Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human

Drug Metabolism and Disposition

Volumn 30, Issue 9, 2002, Pages 1013-1021

  Yuan, Josh J ^a   Yang, Dai Chang ^a   Zhang, Ji Y ^a   Bible Jr , Roy ^a   Karim, Aziz ^a   Findlay, John W A ^a  

^a Global Drug Metabolism   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; SULFINIC ACID DERIVATIVE; SULFONAMIDE; SULFONIC ACID DERIVATIVE; VALDECOXIB; ANTIPRURITIC AGENT; BETA GLUCURONIDASE; CYCLOOXYGENASE 2; ISOENZYME; ISOXAZOLE DERIVATIVE; MEMBRANE PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN;

ADULT; ANALGESIA; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONJUGATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG DISPOSITION; DRUG HALF LIFE; DRUG POTENCY; DRUG SPECIFICITY; DYSMENORRHEA; ENZYME INHIBITION; ENZYME SPECIFICITY; FECES ANALYSIS; HUMAN; HYDROXYLATION; KIDNEY CLEARANCE; MALE; METABOLITE; OSTEOARTHRITIS; OXIDATION; PAIN; PRIORITY JOURNAL; RADIOACTIVITY; RHEUMATOID ARTHRITIS; URINALYSIS; ACUTE DISEASE; BLOOD; CHEMISTRY; CLINICAL TRIAL; FECES; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; ORAL DRUG ADMINISTRATION; URINE;

ACUTE DISEASE; ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIPRURITICS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOOXYGENASE INHIBITORS; FECES; GLUCURONIDASE; HUMAN; ISOENZYMES; ISOXAZOLES; MALE; PAIN; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE; SPECTRUM ANALYSIS, MASS; SULFONAMIDES; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; MASS SPECTROMETRY; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0036707619     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.30.9.1013     Document Type: Article

References (17)

1. Celecoxib: A review of its use in osteoarthritis, rheumatoid arthritis and acute pain
2. Selective cyclooxygenase-2 inhibitors
3. Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis
4. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor
5. Release of nitric oxide upon oxidative metabolism accounts for the vasodilator activity of Piloty's acid
6. 1996 ASPET N-glucuronidation of xenobiotics symposium: Species differences in N-glucuronidation
7. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: A randomized, controlled trial
8. In vivo glucocorticoids regulate cyclooxygenase-2 but not cyclooxygenase-1 in peritoneal macrophages
9. Selective regulaton of cellular cyclooxygenase by dexamethasone and endotoxin in mice
10. Celecoxib for rheumatoid arthritis
11. The discovery and function of COX-2
12. Oxidative release of nitric oxide accounts for guanylyl cyclase stimulating, vasodilator and anti-platelet activity of Piloty's acid: A comparison with Angeli's salt
13. COX-2 inhibitors - Is there cause for concern?
14. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
15. 4-[5-Methyl-3-phenylisoxazol-4-yllbenzenesulfonamide, valdeeoxib: A potent and selective inhibitor of COX-2
16. The future of NSAID therapy: Selective COX-2 inhibitors
17. Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation